Stock Comparison

JNJ vs ZVRA

Johnson & Johnson vs Zevra Therapeutics Inc

The Verdict

ZVRA takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

ZVRA

Zevra Therapeutics Inc

7.5

out of 10

Solid Pick

Head-to-Head

N/A

Market Cap

$589M

N/A

P/E Ratio

7.1

N/A

Profit Margin

78.2%

N/A

Return on Equity

74.6%

N/A

Debt-to-Equity

0.4

Conservative

Overall Risk

Moderate

1.0

DVR Score

7.5

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

ZVRA7.5/10

Score Change Explanation: The previous analysis (2026-03-30, score 9.2/10) heavily weighted the 'significantly de-risked' future approval of Arimoclomol (Niemann-Pick Type C) with a mid-2026 PDUFA date and a 'strong pipeline'. However, updated real-time intelligence reveals material shifts: 1) Zevra has pivoted to a 'single-asset (MIPLYFFA) focus' by selling its SDX portfolio, significantly reduci...

Full ZVRA Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.